I am pleased to announce the launch of the official profile website of Fumihisa Kojima.

Until now, information about the companies and projects I have been involved in has been published across multiple channels, including individual company websites, pages of joint research partners, business plans, public materials, social media, PDF documents, and other sources.

As a result, for those encountering my activities for the first time, it may have been difficult to clearly understand what I am currently working on, how I am connected to each company or project, and how the fields of medicine and biotechnology, Web3, and overseas expansion are related to one another.

This website has been created to organize that information in one place and to present my career, roles, related companies, and the positioning of each business and project in a clear and accessible manner.

I began my career in web production and system development, and later expanded my activities into bioinformatics, GPGPU, crypto assets, AML and compliance, medicine and biotechnology, overseas expansion, and other fields.

At first glance, these fields may appear to be quite different from one another.

However, from my own perspective, there has been a consistent theme throughout my work: to bring technologies and research outcomes into society and move them closer to businesses and projects that can function in the real world.

Currently, mainly through Biozipcode Inc., I am involved in Biozipcode™, research and development aimed at establishing a fundamental treatment for diabetes, 5-ALA, pre-disease, global medical expansion, Web3 projects including GDT, and overseas expansion in Palau, the UAE, and other regions.

At the same time, information related to medicine and research cannot be communicated based on expectations or possibilities alone.

For example, even when using the phrase “diabetes cure,” it does not guarantee any therapeutic effect at this stage. Rather, it refers to research and development efforts aimed at establishing a fundamental treatment for diabetes.

Likewise, with regard to 5-ALA, Biozipcode™, Web3, and overseas medical expansion, I believe it is important to clearly distinguish between the potential of the business and the assumptions, conditions, and points that must be further verified.

This website is not intended to make my activities appear larger than they are. Rather, it is intended to organize the facts, roles, public materials, related companies, and the positioning of each project in a way that can be easily understood from the outside.

I also plan to gradually develop sections such as my profile, career and timeline, positions and affiliated companies, businesses and projects, public materials, disclaimers, and FAQs.

Going forward, I will also use this blog to share the background of my activities, updates on progress, my thoughts, and aspects that cannot be fully conveyed through public materials alone.

Medicine, research, Web3, and overseas expansion are all challenging fields. That is precisely why I will continue striving to communicate information as clearly and accurately as possible while avoiding misunderstandings.

Thank you for your continued support.

Fumihisa Kojima